Concordia International Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company operates through two segments, Concordia International and Concordia North America. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies. This segment's products include Macrobid/Macrodantin to treat bladder infections, such as cystitis and urinary tract infections; Tetroxin drug for severe hypothyroid states; Eltroxin, levothyroxine sodium that treats patients with an underactive thyroid gland; and Fucithalmic, a topical gel treatment for patients suffering with a bacterial infection of the surface lining of the front of the eye. The Concordia North America segment provides Donnatalm, which is used as adjunctive therapy for irritable bowel syndrome; Zonegran, an anti-seizure drug indicated for adjunctive therapy in the treatment of partial seizures in adults with epilepsy; and Plaquenil and Plaquenil AG to treat rheumatoid arthritis and manage the complications of lupus, as well as suppress acute attacks from certain strains of malaria. This segment also offers photodynamic therapy with Photofrin for the treatment of certain forms of cancer that combines a photosensitizing agent with a specific type of laser that emits an exact wavelength of light and power to target cancer cells. The company sells its products through direct sales and local partnerships. The company was formerly known as Concordia Healthcare Corp. and changed its name to Concordia International Corp. in 2016. Concordia International Corp. is headquartered in Oakville, Canada.
Industry, Sector and Symbol
Stock Exchange TSE
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolTSE:CXR
CUSIPN/A
Phone+1-905-8425150
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-44.94%
Return on EquityN/A
Return on Assets-10.59%
Miscellaneous
EmployeesN/A
Outstanding Shares51,284,000
Market CapC$38.43
Concordia International (TSE:CXR) Frequently Asked Questions
What is Concordia International's stock symbol?
Concordia International trades on the Toronto Stock Exchange (TSX) under the ticker symbol "CXR."
How were Concordia International's earnings last quarter?
Concordia International Corp (TSE:CXR) released its quarterly earnings results on Tuesday, May, 15th. The company reported ($0.24) earnings per share for the quarter. The firm earned $192.48 million during the quarter. View Concordia International's Earnings History.
When is Concordia International's next earnings date?
What is the consensus analysts' recommendation for Concordia International?
0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Concordia International in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."
Who are some of Concordia International's key competitors?
Some companies that are related to Concordia International include Emblem (EMC), Cannabics Pharmaceuticals (CNBX), Oxford Biodynamics (OBD), Verseon (VSN), Silence Therapeutics (SLN), Trillium Therapeutics (TRIL), Tiziana Life Sciences (TILS), Bioventix (BVXP), Medicure Inc. Common Stock (MPH), Oncolytics Biotech (ONC), Kitrinor Metals (SCYB), Emblem (EMMBF), Pfenex (PFNX), Oragenics (OGEN) and Asterias Biotherapeutics (AST).
Who are Concordia International's key executives?
Concordia International's management team includes the folowing people:
- Mr. Graeme Neville Duncan, Chief Exec. Officer (Age 44)
- Mr. Francesco Tallarico, Chief Legal Officer & Sec. (Age 35)
- H.R.H. David J. Price, Exec. (Age 55)
- Mr. Adeel Ahmad, Chief Financial Officer (Age 44)
- Mr. Karl Ian Belk, Chief Operations Officer
Has Concordia International been receiving favorable news coverage?
News stories about CXR stock have trended somewhat positive this week, according to Accern Sentiment. The research firm rates the sentiment of media coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Concordia International earned a media sentiment score of 0.06 on Accern's scale. They also assigned news articles about the company an impact score of 46.21 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near future.
How do I buy shares of Concordia International?
Shares of CXR and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Concordia International's stock price today?
One share of CXR stock can currently be purchased for approximately C$0.26.
How big of a company is Concordia International?
Concordia International has a market capitalization of C$38.43 million.
How can I contact Concordia International?
Concordia International's mailing address is 277 Lakeshore Rd E Suite 302, OAKVILLE, ON L6J 1H9, Canada. The company can be reached via phone at +1-905-8425150.
MarketBeat Community Rating for Concordia International (TSE CXR)
MarketBeat's community ratings are surveys of what our community members think about Concordia International and other stocks. Vote "Outperform" if you believe CXR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CXR will underperform the S&P 500 over the long term. You may vote once every thirty days.
